2023
Neuroimaging-based classification of PTSD using data-driven computational approaches: A multisite big data study from the ENIGMA-PGC PTSD consortium
Zhu X, Kim Y, Ravid O, He X, Suarez-Jimenez B, Zilcha-Mano S, Lazarov A, Lee S, Abdallah C, Angstadt M, Averill C, Baird C, Baugh L, Blackford J, Bomyea J, Bruce S, Bryant R, Cao Z, Choi K, Cisler J, Cotton A, Daniels J, Davenport N, Davidson R, DeBellis M, Dennis E, Densmore M, deRoon-Cassini T, Disner S, Hage W, Etkin A, Fani N, Fercho K, Fitzgerald J, Forster G, Frijling J, Geuze E, Gonenc A, Gordon E, Gruber S, Grupe D, Guenette J, Haswell C, Herringa R, Herzog J, Hofmann D, Hosseini B, Hudson A, Huggins A, Ipser J, Jahanshad N, Jia-Richards M, Jovanovic T, Kaufman M, Kennis M, King A, Kinzel P, Koch S, Koerte I, Koopowitz S, Korgaonkar M, Krystal J, Lanius R, Larson C, Lebois L, Li G, Liberzon I, Lu G, Luo Y, Magnotta V, Manthey A, Maron-Katz A, May G, McLaughlin K, Mueller S, Nawijn L, Nelson S, Neufeld R, Nitschke J, O'Leary E, Olatunji B, Olff M, Peverill M, Phan K, Qi R, Quidé Y, Rektor I, Ressler K, Riha P, Ross M, Rosso I, Salminen L, Sambrook K, Schmahl C, Shenton M, Sheridan M, Shih C, Sicorello M, Sierk A, Simmons A, Simons R, Simons J, Sponheim S, Stein M, Stein D, Stevens J, Straube T, Sun D, Théberge J, Thompson P, Thomopoulos S, van der Wee N, van der Werff S, van Erp T, van Rooij S, van Zuiden M, Varkevisser T, Veltman D, Vermeiren R, Walter H, Wang L, Wang X, Weis C, Winternitz S, Xie H, Zhu Y, Wall M, Neria Y, Morey R. Neuroimaging-based classification of PTSD using data-driven computational approaches: A multisite big data study from the ENIGMA-PGC PTSD consortium. NeuroImage 2023, 283: 120412. PMID: 37858907, PMCID: PMC10842116, DOI: 10.1016/j.neuroimage.2023.120412.Peer-Reviewed Original Research
2022
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion On Drug Safety 2022, 21: 777-787. PMID: 35416105, DOI: 10.1080/14740338.2022.2066651.Peer-Reviewed Original ResearchConceptsLong-term safetyClinical trialsRacemic ketamineLong-term safety effectsRapid-acting antidepressant effectsLower urinary tract symptomsKetamine/esketamineTreatment-resistant depressionUrinary tract symptomsCommon side effectsTreatment of depressionLong-term impairmentElevated heart ratePhase three clinical trialsTract symptomsAntidepressant effectsBlood pressureIncreased riskBladder pathologyEsketamineHeart ratePsychiatric disordersSide effectsCognitive impairmentHigh dosesImaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry 2022, 27: 2273-2281. PMID: 35165397, PMCID: PMC9133063, DOI: 10.1038/s41380-022-01465-2.Peer-Reviewed Original ResearchConceptsKetamine's therapeutic effectsMajor depressive disorderTherapeutic effectPositron emission tomographyPosttraumatic stress disorderHealthy controlsSynaptic connectionsSynaptic vesicle protein 2APost-synaptic mechanismsEffects of ketamineDiscovery of ketamineNon-human primatesAntidepressant effectsDepressive disorderSingle administrationSynaptic densityPsychiatric disordersDepression severityKetamineEmission tomographyTerminal densityLiving brainStress disorderRobust reductionDissociative symptoms
2021
Risks and Benefits of Cannabis and Cannabinoids in Psychiatry
Hill KP, Gold MS, Nemeroff CB, McDonald W, Grzenda A, Widge AS, Rodriguez C, Kraguljac NV, Krystal JH, Carpenter LL. Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. American Journal Of Psychiatry 2021, 179: 98-109. PMID: 34875873, DOI: 10.1176/appi.ajp.2021.21030320.Peer-Reviewed Original ResearchConceptsPsychiatric disordersRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialTherapeutic useEvidence basePlacebo-controlled trialManagement of painBenefits of cannabisSearch of PubMedMental health cliniciansCurrent evidence basePotential side effectsSpecific medical conditionsPsychiatric indicationsFDA indicationClinical trialsHealth cliniciansMedical conditionsReference listsSide effectsChronic cannabisPsychotic disordersDrug AdministrationAdditional articlesMedicinal cannabisArtificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom
Lee EE, Torous J, De Choudhury M, Depp CA, Graham SA, Kim HC, Paulus MP, Krystal JH, Jeste DV. Artificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2021, 6: 856-864. PMID: 33571718, PMCID: PMC8349367, DOI: 10.1016/j.bpsc.2021.02.001.Peer-Reviewed Original ResearchConceptsMental health careMental illnessHealth careMental health care providersHigh-risk individualsHealth care providersElectronic health recordsHigh morbiditySound careStudy groupAmerican CollegeCare providersPsychiatric disordersOwn careProdromal stageClinical diagnosisBrain imagingHealth recordsIllnessCareClinical applicationHealth care fieldIllustrative publicationsTreatmentNeurobiological research
2020
Multivariate genome-wide analysis of education, socioeconomic status and brain phenome
Wendt FR, Pathak GA, Lencz T, Krystal JH, Gelernter J, Polimanti R. Multivariate genome-wide analysis of education, socioeconomic status and brain phenome. Nature Human Behaviour 2020, 5: 482-496. PMID: 33349686, PMCID: PMC8068566, DOI: 10.1038/s41562-020-00980-y.Peer-Reviewed Original ResearchConceptsPsychosocial factorsSocioeconomic statusPsychiatric disordersBipolar disorderGenetic riskNeuronal cell typesMajor depressionTourette syndromeBrain morphologyDisordersImaging phenotypesCell typesRisky behaviorsPsychopathologyGenetic overlapRiskGenetic discoveriesPsychiatric traitsStatusSyndromeTransdiagnostic, Connectome-Based Prediction of Memory Constructs Across Psychiatric Disorders
Barron DS, Gao S, Dadashkarimi J, Greene AS, Spann MN, Noble S, Lake EMR, Krystal JH, Constable RT, Scheinost D. Transdiagnostic, Connectome-Based Prediction of Memory Constructs Across Psychiatric Disorders. Cerebral Cortex 2020, 31: 2523-2533. PMID: 33345271, PMCID: PMC8023861, DOI: 10.1093/cercor/bhaa371.Peer-Reviewed Original ResearchConceptsMacroscale brain networksIndividual differencesBrain networksMemory deficitsFunctional connectivityAttention deficit hyper-activity disorderTask-based functional MRI dataLong-term memoryWhole-brain functional connectivityDiagnostic groupsWhole-brain patternsDefault mode networkFunctional MRI dataHuman Connectome ProjectPsychiatric disordersMemory constructsMemory performanceTransdiagnostic sampleBrain correlatesMode networkFunctional connectomeConnectome ProjectLimbic networkHealthy participantsMemoryPredictive Processing in Mental Illness: Hierarchical Circuitry for Perception and Trauma
Kaye AP, Krystal JH. Predictive Processing in Mental Illness: Hierarchical Circuitry for Perception and Trauma. Journal Of Psychopathology And Clinical Science 2020, 129: 629-632. PMID: 32757606, DOI: 10.1037/abn0000628.Peer-Reviewed Original ResearchConceptsTrauma-related disordersPredictive processingDisorders of perceptionNeural circuitsHigher-order predictionsAbnormal psychologyPrediction errorSensory stimuliPredictive codingHierarchical circuitryPrior beliefsNew sensory dataPerceptionBayesian processPsychiatric disordersPsychotic disordersHierarchical viewHierarchical organizationMental illnessSensory dataBeliefsDisordersFuture directionsComputational layerProcessingKetamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?
Abdallah CG, Krystal JH. Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression? Behavioural Brain Research 2020, 390: 112628. PMID: 32407817, PMCID: PMC7316409, DOI: 10.1016/j.bbr.2020.112628.Peer-Reviewed Original ResearchConceptsChronic stress pathologyRapid acting antidepressantsHigh treatment resistanceActing antidepressantsChronic courseClinical evidenceLeading causeTreatment resistancePsychiatric disordersStress pathologyDepressionLarge proportionAntidepressantsPatientsReviewKetamineIllnessPathologyComprehensive review
2019
Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET
Holmes SE, Gallezot JD, Davis MT, DellaGioia N, Matuskey D, Nabulsi N, Krystal JH, Javitch JA, DeLorenzo C, Carson RE, Esterlis I. Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET. Cerebrovascular And Brain Metabolism Reviews 2019, 40: 2254-2264. PMID: 31744389, PMCID: PMC7585925, DOI: 10.1177/0271678x19886316.Peer-Reviewed Original ResearchConceptsEffects of ketamineKetamine infusionGlutamate transmissionMetabotropic glutamate receptor 5Ketamine-induced effectsKetamine-induced changesGlutamate receptor 5Promising treatment targetDrug challenge studiesTwo-tissue compartment modelMGluR5 radioligandBlood pressureMGluR5 availabilityBaseline scanOutcome measuresHealthy subjectsHeart ratePsychiatric disordersReceptor 5Modulatory effectsMGluR5Treatment targetsChallenge studiesArterial input functionChallenge paradigmEnhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development
Kaffman A, White JD, Wei L, Johnson FK, Krystal JH. Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development. Methods In Molecular Biology 2019, 2011: 3-22. PMID: 31273690, PMCID: PMC6895673, DOI: 10.1007/978-1-4939-9554-7_1.Peer-Reviewed Original ResearchConceptsPreclinical researchAnimal modelsPsychiatric conditionsLower clinical success ratesClinical success rateCommon psychiatric conditionsPsychiatric clinical trialsClinical trialsNew pharmacotherapiesMore effective interventionsPreclinical workPsychiatric disordersPsychiatric pathophysiologyMental illnessSystematic reviewEffective interventionsAnimal experimentsDrug development processSuccess rateDrug developmentHuman psychopathologyPharmaceutical companiesPredictive validityLarge pharmaceutical companiesAnimals
2017
Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson S, Ostroff R, Katz R, Krystal J. Ketamine: A Promising Rapid-Acting Antidepressant. 2017, 223-239. DOI: 10.1007/978-981-10-6577-4_16.Peer-Reviewed Original ResearchMood disordersDeficiency hypothesisInitiation of therapyRapid antidepressant effectsRapid acting antidepressantsEvidence-based treatmentsLong-term riskMood disorders researchRelapse prevention strategiesEfficient therapeutic targetMechanism of actionOral antidepressantsAntidepressant effectsGlutamatergic receptorsGlutamatergic systemNovel antidepressantsSingle doseClinical trialsKetamine exposureRelated symptomsLong-term effectsPsychiatric disordersPrevention strategiesTherapeutic targetDrug AdministrationTargeted neural network interventions for auditory hallucinations: Can TMS inform DBS?
Taylor JJ, Krystal JH, D'Souza DC, Gerrard JL, Corlett PR. Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS? Schizophrenia Research 2017, 195: 455-462. PMID: 28969932, PMCID: PMC8141945, DOI: 10.1016/j.schres.2017.09.020.Peer-Reviewed Original ResearchConceptsDeep brain stimulationTranscranial magnetic stimulationAuditory hallucinationsBrain stimulationCombination of TMSTreatment-refractory schizophreniaAberrant neural networksRelevant neural networksNon-invasive formNeuromodulatory interventionsMagnetic stimulationPsychiatric disordersSymptom clusteringTherapeutic interventionsClinical decisionInvasive formNeurophysiological dataCausal evidencePsychiatric constructsStimulationNetwork modulationInterventionNeural networkSafety concernsInvestigational probesMetabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies
Esterlis I, Holmes SE, Sharma P, Krystal JH, DeLorenzo C. Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies. Biological Psychiatry 2017, 84: 95-105. PMID: 29100629, PMCID: PMC5858955, DOI: 10.1016/j.biopsych.2017.08.025.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPositron emission tomography studyEmission tomography studiesMGluR5 modulationAntidepressant responseStress disorderBipolar disorderStress-related psychiatric disordersTomography studyAntagonism of mGluR5Ketamine’s antidepressant responseSignificant side effectsPromising therapeutic targetReceptor imaging studiesPosttraumatic stress disorderMDD heterogeneityManic mood statesAntidepressant efficacyObsessive-compulsive disorderDepressive disorderSubtype 5Neurotransmitter systemsPsychiatric disordersReceptor 5Side effectsMoral injury in U.S. combat veterans: Results from the national health and resilience in veterans study
Wisco BE, Marx BP, May CL, Martini B, Krystal JH, Southwick SM, Pietrzak RH. Moral injury in U.S. combat veterans: Results from the national health and resilience in veterans study. Depression And Anxiety 2017, 34: 340-347. PMID: 28370818, DOI: 10.1002/da.22614.Peer-Reviewed Original ResearchMental disordersNational HealthCombat veteransU.S. combat veteransCurrent mental disorderPast psychiatric disordersPopulation-based sampleCombat severityMental health problemsMoral Injury Events ScaleFunctional outcomeMoral injuryWhite racePsychiatric disordersHealth problemsU.S. veteransSuicidal ideationVeterans StudySuicide attemptsInjurious eventsCombat exposureSociodemographic variablesDisordersExposure historyVeteransImpaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective
Krystal JH, Anticevic A, Yang GJ, Dragoi G, Driesen NR, Wang XJ, Murray JD. Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective. Biological Psychiatry 2017, 81: 874-885. PMID: 28434616, PMCID: PMC5407407, DOI: 10.1016/j.biopsych.2017.01.004.Peer-Reviewed Original ResearchConceptsNeural activityNeural ensemblesComputational neuroscience perspectiveHigher cognitive functionsNeuroscience perspectiveDevelopmental perspectiveDevelopmental correlatesCognitive functionNegative functional consequencesCortical networksComputational neuroscienceNeural codeCortical activityCognitive impairmentNeural dysfunctionAspartate glutamate receptor antagonistTemporal tuningSpatial tuningGlutamate receptor antagonistsPathophysiology of schizophreniaNeural network functionSchizophreniaPsychiatric disordersBalance of excitationInput-output curves
2016
Clinical Heterogeneity Arising from Categorical and Dimensional Features of the Neurobiology of Psychiatric Diagnoses: Insights from Neuroimaging and Computational Neuroscience
Krystal J, Anticevic A, Murray J, Glahn D, Driesen N, Yang G, Wang X. Clinical Heterogeneity Arising from Categorical and Dimensional Features of the Neurobiology of Psychiatric Diagnoses: Insights from Neuroimaging and Computational Neuroscience. 2016, 293-316. DOI: 10.7551/mitpress/10936.003.0023.Peer-Reviewed Original ResearchPsychiatric disordersMechanisms of psychiatric disordersModel psychiatric disordersPsychiatric nosologyPsychological assessmentPsychiatric diagnosingModern psychiatryPsychiatric issuesNeurobiologyPsychiatristsNeurological analysisPsychiatryDisordersComputational neuroscienceClinical heterogeneityNeuroimagingNosologyNeuroscienceNeuroscientistsComputational neuroscientistsCategorizationGlutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies
Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neuroscience Letters 2016, 649: 147-155. PMID: 27916636, PMCID: PMC5482215, DOI: 10.1016/j.neulet.2016.11.064.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderPsychiatric disordersStress-related psychiatric disordersAlternative pharmacologic treatmentsPutative neurobiological underpinningsGlutamate-modulating agentsTrauma-related disordersGlutamatergic abnormalitiesGlutamate dysregulationPharmacologic treatmentPharmacologic interventionsGlutamatergic functionGlutamate neurotransmissionMillions of individualsHuman studiesCardinal featuresStress disorderDisordersNeurobiological underpinningsRelated future directionsEvidenceChronicDysfunctionNeurotransmissionSubject dataPTSD: from neurobiology to pharmacological treatments
Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH. PTSD: from neurobiology to pharmacological treatments. European Journal Of Psychotraumatology 2016, 7: 31858. PMID: 27837583, PMCID: PMC5106865, DOI: 10.3402/ejpt.v7.31858.Peer-Reviewed Original ResearchPosttraumatic stress disorderPharmacological treatmentPathophysiology of PTSDFirst-line pharmacotherapyMultiple neurobiological systemsEtiology of PTSDFull remissionTherapeutic effectPsychiatric disordersPharmacologic targetStress disorderNeurobiological systemsPathophysiologyFuture targetsTreatmentTraumatic eventsDisordersRemissionPharmacotherapyEtiologyInjurySymptomsYearsWeeksProbable Posttraumatic Stress Disorder in the US Veteran Population According to DSM-5: Results From the National Health and Resilience in Veterans Study.
Wisco BE, Marx BP, Miller MW, Wolf EJ, Mota NP, Krystal JH, Southwick SM, Pietrzak RH. Probable Posttraumatic Stress Disorder in the US Veteran Population According to DSM-5: Results From the National Health and Resilience in Veterans Study. The Journal Of Clinical Psychiatry 2016, 77: 1503-1510. PMID: 27631148, DOI: 10.4088/jcp.15m10188.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAfghan Campaign 2001-AgedCohort StudiesCombat DisordersComorbidityCross-Sectional StudiesDiagnostic and Statistical Manual of Mental DisordersFemaleFollow-Up StudiesHealth SurveysHumansIraq War, 2003-2011Life Change EventsMaleMental DisordersMiddle AgedResilience, PsychologicalStress Disorders, Post-TraumaticSurveys and QuestionnairesVeteransYoung AdultConceptsProbable posttraumatic stress disorderDSM-5 posttraumatic stress disorderPosttraumatic stress disorderUS veteran populationPsychiatric comorbidityUS veteransNational HealthVeteran populationVeterans StudyStress disorderPTSD symptomsOdds of moodHigh public health burdenPublic health burdenPopulation-based samplePast-month prevalenceDSM-5Specific PTSD symptomsHigh rateWeighted lifetimeNew symptomsHealth burdenLow prevalencePsychiatric disordersPTSD Checklist-5